Literature DB >> 35986192

Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer.

Yanshu Liang1, Shuang Zhi2, Zhixia Qiao3, Fancui Meng4.   

Abstract

AZD3759 is an epidermal growth factor receptor inhibitor with good blood-brain barrier permeability, demonstrating encouraging activity against central nervous system metastases. However, the underlying mechanism was still unclear. In this study, the interaction between AZD3759 and membrane was studied with 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer as a model lipid. Both the cationic and neutral state of AZD3759 were considered in the simulations, and the results show that cationic AZD3759 forms more hydrogen bonds with bilayer than neutral AZD3759, and Coulombic interaction has great effects in the transmembrane process of cationic AZD3759. AZD3759 prefers to reside in the interface between the hydrophilic headgroup region and hydrophobic region of bilayer, and the chloroflurobenzene moiety plays a crucial role in the insertion of AZD3759. PMF results suggest that the hydrophobic region of DMPC bilayer is permeable by AZD3759. Understanding the transmembrane mechanism of AZD3759 at molecular level may provide useful information to the design and optimization of anti-tumor drugs with improved BBB penetration. • The penetration mechanism of AZD3759 with DMPC bilayer was studied by molecular dynamics simulations. • Neutral AZD3759 could penetrate deeper into DMPC bilayer than protonated AZD3759. • The chloroflurobenzene moiety plays a significant role in the insertion of AZD3759 into DMPC bilayer. • The electrostatic interaction is the driving force for the initial binding of AZD3759 to DMPC bilayer. • Our findings may enhance the mechanism understanding of drugs with good BBB permeability.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  AZD3759; Blood–brain barrier; DMPC; Molecular dynamics; Potential of mean force

Mesh:

Substances:

Year:  2022        PMID: 35986192     DOI: 10.1007/s00894-022-05266-w

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   2.172


  40 in total

1.  Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

Authors:  Qingbei Zeng; Jiabing Wang; Ziqiang Cheng; Kan Chen; Peter Johnström; Katarina Varnäs; David Yunzhi Li; Zhen Fan Yang; Xiaolin Zhang
Journal:  J Med Chem       Date:  2015-10-09       Impact factor: 7.446

2.  AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.

Authors:  Zhenfan Yang; Qiuli Guo; Yingchun Wang; Kan Chen; Lin Zhang; Ziqiang Cheng; Yanping Xu; Xiaolu Yin; Yu Bai; Sarit Rabbie; Dong-Wan Kim; Myung-Ju Ahn; James Chih-Hsin Yang; Xiaolin Zhang
Journal:  Sci Transl Med       Date:  2016-12-07       Impact factor: 17.956

Review 3.  Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

Authors:  Timothy P Heffron
Journal:  J Med Chem       Date:  2016-08-03       Impact factor: 7.446

4.  Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.

Authors:  Xue Li; Yingchun Wang; Jia Wang; Tianwei Zhang; Li Zheng; Zhenfan Yang; Ligang Xing; Jinming Yu
Journal:  Int J Cancer       Date:  2018-03-01       Impact factor: 7.396

Review 5.  The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.

Authors:  Dimitry A Chistiakov; Ivan V Chekhonin; Vladimir P Chekhonin
Journal:  Eur J Pharmacol       Date:  2017-06-02       Impact factor: 4.432

6.  Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability.

Authors:  Jurgen Mensch; Anouche Melis; Claire Mackie; Geert Verreck; Marcus E Brewster; Patrick Augustijns
Journal:  Eur J Pharm Biopharm       Date:  2010-01-11       Impact factor: 5.571

7.  Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Authors:  Myung-Ju Ahn; Dong-Wan Kim; Byoung Chul Cho; Sang-We Kim; Jong Seok Lee; Jin-Seok Ahn; Tae Min Kim; Chia-Chi Lin; Hye Ryun Kim; Thomas John; Steven Kao; Jonathan W Goldman; Wu-Chou Su; Ronald Natale; Sarit Rabbie; Bryony Harrop; Philip Overend; Zhenfan Yang; James Chih-Hsin Yang
Journal:  Lancet Respir Med       Date:  2017-10-19       Impact factor: 30.700

Review 8.  Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.

Authors:  J Remon; C E Steuer; S S Ramalingam; E Felip
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

Review 9.  A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.

Authors:  Madan M Kwatra
Journal:  Curr Cancer Drug Targets       Date:  2017       Impact factor: 3.428

Review 10.  Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective.

Authors:  Baichen Xiong; Yuanyuan Wang; Ying Chen; Shuaishuai Xing; Qinghong Liao; Yao Chen; Qi Li; Wei Li; Haopeng Sun
Journal:  J Med Chem       Date:  2021-09-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.